This retrospective observational study evaluated racial disparities among Black and White patients with multiple myeloma (MM). We included patients from a longitudinal de-identified EHR-derived database who had ≥2 visits recorded on or after 1/1/2011, documented treatment, and race listed as White or Black. Black patients (n = 1172) were more likely female (54.8%/42.9%) and younger (<65 years, 40.8%/30.8%) than White patients (n = 4637). Unadjusted median real-world overall survival (rwOS) indexed to first-line of therapy (LOT) was 64.6 months (95% CI: 57.8–74.0) for Blacks and 54.5 months (95% CI: 50.9–56.2) for Whites. Adjusted rwOS estimates (for sex, age at index date, and practice type) to either first- (aHR = 0.94; 95% CI: 0.84–1.06) or second-LOT (aHR = 0.90; 95% CI: 0.77–1.05) were similar. Unadjusted derived response rate (dRR) during first-LOT was 84.8% (95% CI: 80.7–88.1) for Blacks and 86.9% (95% CI: 85.0–88.5) for Whites (odds ratio [OR] = 0.78 [95% CI: 0.57–1.10]); in second-LOT, 67.2% (95% CI: 58.4–75.0) for Blacks and 72.4% (95% CI: 68.1–76.3) for Whites (OR = 0.72 [95% CI: 0.46–1.13]). High representation of Black patients enabled this robust analysis, albeit with limitations inherent to the observational data source, the retrospective design, and the analytic use of newly derived endpoints requiring further validation.

这项回顾性观察研究评估了多发性骨髓瘤 (MM) 黑人和白人患者的种族差异。我们纳入了来自纵向去识别 EHR 衍生数据库的患者，这些患者在 2011 年 1 月 1 日或之后记录了 ≥2 次就诊、有记录的治疗以及列为白人或黑人的种族。黑人患者（n  = 1172）比白人患者（n = 4637）。与一线治疗 (LOT) 挂钩的未经调整的中位真实世界总生存期 (rwOS) 为黑人 64.6 个月 (95% CI: 57.8–74.0)，白人为 54.5 个月 (95% CI: 50.9–56.2)。将 rwOS 估计值（针对性别、索引日期的年龄和实践类型）调整为第一（aHR = 0.94；95% CI：0.84–1.06）或第二批次（aHR = 0.90；95% CI：0.77–1.05）是相似的。首次 LOT 期间未经调整的衍生反应率 (dRR) 为黑人 84.8% (95% CI: 80.7–88.1)，白人为 86.9% (95% CI: 85.0–88.5)（优势比 [OR] = 0.78 [95% CI：0.57–1.10]）；在第二批中，黑人为 67.2% (95% CI: 58.4–75.0)，白人为 72.4% (95% CI: 68.1–76.3) (OR = 0.72 [95% CI: 0.46–1.13])。黑人患者的高代表性使这种稳健的分析成为可能，尽管观察数据源、回顾性设计、